The three-year programme is the brainchild of global biopharmaceutical company, Novo Nordisk, in partnership with the American Society of Haematology (ASH), and will be rolled out in seven African ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

Albertsons CEO Susan Morris said she had to "double-check the numbers" when she saw how much cottage cheese the chain was selling.

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...